Sidoti Csr Cuts Earnings Estimates for Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Research analysts at Sidoti Csr reduced their FY2026 earnings per share (EPS) estimates for shares of Phio Pharmaceuticals in a report released on Monday, November 17th. Sidoti Csr analyst A. Hantman now forecasts that the company will post earnings per share of ($1.06) for the year, down from their prior estimate of ($1.05). The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. Sidoti Csr also issued estimates for Phio Pharmaceuticals’ FY2027 earnings at ($0.79) EPS.

PHIO has been the subject of several other research reports. Wall Street Zen lowered shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Phio Pharmaceuticals in a report on Friday, August 15th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Stock Performance

PHIO stock opened at $1.19 on Thursday. Phio Pharmaceuticals has a one year low of $0.97 and a one year high of $9.79. The firm has a market cap of $6.82 million, a price-to-earnings ratio of -0.37 and a beta of 0.97. The firm has a 50-day simple moving average of $2.00 and a two-hundred day simple moving average of $2.14.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01.

Institutional Investors Weigh In On Phio Pharmaceuticals

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Geode Capital Management LLC increased its stake in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,694 shares of the company’s stock after buying an additional 16,108 shares during the quarter. Geode Capital Management LLC owned about 1.20% of Phio Pharmaceuticals worth $136,000 as of its most recent SEC filing. Institutional investors own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.